Case Report

Active Mycobacterium Infection Due to Intramuscular BCG Administration Following Multi-Steps Medication Errors

Abstract

Bacillus Calmette-Guérin (BCG) is indicated for treatment of primary or relapsing flat urothelial cell carcinoma in situ (CIS) of the urinary bladder. Disseminated infectious complications occasionally occur due to BCG as a vaccine and intravesical therapy.  Intramuscular (IM) or Intravenous (IV) administrations of BCG are rare medication errors which are more probable to produce systemic infections. This report presents 13 years old case that several steps medication errors occurred consequently from physician handwriting, pharmacy dispensing, nursing administration and patient family. The physician wrote βHCG instead of HCG in the prescription. βHCG was read as BCG by the pharmacy staff and 6 vials of intravesical BCG were administered IM twice a week for 3 consecutive weeks. The patient experienced fever and chills after each injection, but he was admitted 2 months after first IM administration of BCG with fever and pancytopenia. Unfortunately four month after using drug, during second admission duo to cellulitis at the sites of BCG injection the physicians diagnosed the medication error. Using handwritten prescription and inappropriate abbreviations, spending inadequate time for taking a brief medical history in pharmacy, lack of verifying name, dose and wrote before medication administration and lack of considering medication error as an important differential diagnosis had roles to occur this multi-steps medication error.

Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette- guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86-91.

Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143:502-6.

Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette- Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;(3):CD003231.

Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682-6.

de Reijke TM, Kurth KH, Sylvester RJ, et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol 2005; 173:405-9.

Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis 2000; 31 (Suppl 3):S91-3.

Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170:964-9.

Mungan NA, Witjes JA. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol 1998; 82:213-23.

Lotte A, Wasz-Höckert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984; 21: 107-93.

Catalona WJ, Ratliff TL. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu 1990; 22:363-78.

Grange J.Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998;1(2):84-8.

Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19: 565-72.

Williams DE. Mycobacterium bovis BCG infection in humans. In: Thoen CO, Steele JH, editors. Mycobacterium bovis infection in animals and humans. Ames: Iowa State University Press, 1995: 47-61.

DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL. Antibiotic and steroid therapy of massive bacillus Calmette- Guérin toxicity. J Urol 1992; 147: 738-42.

Leebeek FW, Ouwendijk RJ, Kolk AH, Meek JC, Nienhuis JE, Dingemans- Dumas AM. Granulomatous hepatitis caused by bacillus Calmette-Guérin (BCG) infection after BCG bladder instillation. Gut 1996; 38: 616-8.

NPSA. Design for Patient Safety. A Guide to the Design of the Dispensing Environment. London: NPSA, 2007.

James KL, Barlowa D, McArtney R, Hiom S, Roberts D , Whittlesea C. The use of the critical incident technique to investigate prevented dispensing incidents developed by key informant interviews, focus group and observation. Int J Pharm Pract 2007; 15(Suppl. 1): A31.

Spencer MG, Smith AP. A multicentre study of dispensing errors in British hospitals. Int J Pharm Pract 1993; 2: 142–6.

James KL, Barlowa D, McArtney R, Hiom S, Roberts D , Whittlesea C. Incidence, type and causes of dispensing errors: a review of the literature. Int J Pharm Pract 2009; 17: 9-30.

Lalkin A, Kapur BM, Verjee ZH, Koren G. Contamination of antibiotics resulting in severe pediatric methadone poisoning. Ann Pharmacother 1999; 33: 314–7.

Henderson J, Anderson WD, Jawad MA. Potassium permanganate burn due to a dispensing error. Burns 2003; 29: 401–2.

Smith J. Building a Safer NHS for Patient. Improving Medication Safety. London: Department of Health, 2004.

Buylaert W, Sassenbroeck DV, Verstraete A, Hemelsoet D, Monsieurs K. A pharmacy dispensing error leading to hyoscine hydrobromide overdose. Br J Clin Pharmacol 2005;59: 123–4.

Koukol SC, DeHaven JL, Riggs DR, Lamm DL. Drug therapy of bacillus Calmette-Guérin sepsis. Urol Res 1995; 22: 373-6.

BCG drug information. http://www.rxlist.com/theracys-drug/indications- dosage.

Shelley MD, Court JB, Kynaston H, et al. Intravesical Bacillus Calmette- Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000;(4):CD001986.

Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F. Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study. Pediatrics 1996; 98(4 Pt 1):774-8.

Kathman DD, Oliveira PM. Disseminated Bacillus Calmette-Guérin (BCG) Infection as a Consequence of Immunotherapy for Bladder Carcinoma. Chest 2012;142;156A.

Akbulut Z, Canda AE, Atmaca AF, Cimen HI, Hasanoglu C, Balbay MD. BCG sepsis following inadvertent intravenous BCG administration for the treatment of bladder cancer can be effectively cured with anti-tuberculosis medications. N Z Med J 2010;123(1325):72-7.

Yarmohammadi A, Ahmadiani H, Abolbashari M. Results of inadvertent administration of bacillus Calmette-Guerin for treatment of transitional cell carcinoma of bladder. Urol J 2007;4(2): 121-2.

Pasteur M, Hall D. The effects of inadvertent intramuscular injection of BCG vaccine. Scand J Infect Dis 2001;33(6):473-4.

Institute of Medicine, Committee on Identifying and Preventing Medication Errors, Preventing Medication Errors. National Academies Press; 2007: 124-5.

American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm.1993; 50:305-14.

–14 Reason J. Human error: models and management. BMJ 2000; 320:768– 70.

Rafati MR, Ahmadi AH. Report of thirty one admissions due to adverse drug reactions in Bo-Ali Sina hospital, Sari, Iran. J Mazand Univ Med Sci 2009; 19(71): 67-70 (Persian).

Files
IssueVol 2, No 3 (Summer 2014) QRcode
SectionCase Report(s)
Keywords
BCG Vaccine Medication Error Intramuscular Injections

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Rafati MR, Kouchaki B. Active Mycobacterium Infection Due to Intramuscular BCG Administration Following Multi-Steps Medication Errors. J Pharm Care. 2015;2(3):132-136.